Voya Investment Management LLC Lowers Position in Boston Scientific Corporation $BSX

Key Points

• Voya Investment Management LLC has reduced its stake in Boston Scientific Corporation by 13.8%, owning approximately 3.96 million shares worth $398.9 million after selling 636,094 shares during the first quarter.
• Insider transactions have been notable, with Director Yoshiaki Fujimori and Director Edward J. Ludwig both selling a total of 6,901 shares, indicating a significant decrease in their respective positions.
• Boston Scientific reported a 22.8% year-over-year revenue increase along with earnings per share of $0.75, exceeding analyst expectations of $0.72, and has set its Q3 2025 guidance at $0.700-0.720 EPS.

Voya Investment Management LLC lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 3,956,684 shares of the medical equipment provider's stock after selling 636,094 shares during the period. Voya Investment Management LLC owned about 0.27% of Boston Scientific worth $398,924,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Investment Management Corp VA ADV acquired a new stake in Boston Scientific in the fourth quarter valued at $25,000. Sunbeam Capital Management LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the first quarter worth about $27,000. Finally, Ameriflex Group Inc. acquired a new position in shares of Boston Scientific in the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

BSX has been the subject of a number of recent analyst reports. Robert W. Baird increased their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Truist Financial lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $121.00 price objective on shares of Boston Scientific in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $118.04.

Boston Scientific Stock Down 1.6%

Shares of BSX stock traded down $1.63 on Friday, reaching $102.71. 10,541,837 shares of the company were exchanged, compared to its average volume of 6,378,869. The company has a market cap of $152.19 billion, a price-to-earnings ratio of 61.14, a PEG ratio of 2.47 and a beta of 0.65. The company has a 50-day moving average of $104.86 and a 200-day moving average of $102.27. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue was up 22.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 over the last ninety days. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.